Biography
Amy has a BSc in Molecular & Cellular Biology and an MSc in Clinical Neuroscience and a background in scientific laboratory-based research. Amy joined the University of Cambridge in 2017, as a study coordinator for IMAGINE-ID, a project assessing the genomic impact of intellectual disability on neurodevelopment and mental health in children/young adults, in the Department of Medical Genetics. She moved to the Department of Public Health & Primary Care in 2019, managing a portfolio of recall-by-genotype studies, investigating genetic variants associated with cardiovascular disease in the Cardiovascular Epidemiology Unit. Amy undertook a secondment in the Primary Care Unit in 2022, working on the SAFER Trial (a randomised controlled trial to determine if screening for atrial fibrillation in primary care is effective and cost effective in reducing stroke compared to current practice), before taking up a position with the CanRisk programme (funded by Cancer Research UK) in 2023. In this role, Amy was responsible for coordinating two large clinical studies: 1) CanRisk-ClinGen: A multi-centre randomised controlled trial in UK NHS Clinical Genetics services, trialling a new clinical pathway which gives an up-front comprehensive breast cancer risk assessment. 2) CanRisk-GP: A multi-centre feasibility study in primary care, offering breast cancer risk assessments to women in the general population, via their GP. Amy is now working on the PREVENT-Breast study to evaluate the impact of a culturally tailored proactive breast cancer risk assessment pathway in primary care.
Research
Amy has an active interest in patient/public involvement and engagement (PPIE) especially in the area of health research. Amy is particularly interested in involving patients/public to improve and develop services, as well as helping guide study design/patient experience of research. She has been involved in a wide range of PPIE activities, both in her professional roles and in a voluntary capacity.
